SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid community frustration over stagnant price action and debates surrounding the upcoming legislative clarity, which many investors view as the necessary catalyst for institutional adoption. Despite these headwinds, the community remains deeply divided, with some users aggressively accumulating on dips while others express exhaustion over persistent delays and perceived lack of momentum.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as investors debate the potential for a rebound, with supporters highlighting upcoming catalysts and the community pushing for renewed momentum to break key resistance levels. While many users focus on the speculative nature of the project and its meme-coin status, others are actively coordinating buy campaigns to regain previous market highs.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased community chatter driven by its recent quantum-security recognition and ongoing infrastructure developments. Investors are actively debating the token's long-term utility versus its extended price consolidation, with many focused on accumulating positions ahead of anticipated sector-wide shifts.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending as investors digest the bank's recent earnings report, which highlighted record trading revenue while simultaneously noting caution regarding rising geopolitical and economic risks. The community is actively debating the bank's cautious forward guidance, its role in evolving AI and private credit sectors, and the broader implications of these developments for financial markets.

Brown & Brown, Inc. is an insurance agency, wholesale brokerage, insurance program and service organization. It engages in the provision of insurance brokerage services and casualty insurance underwriting services. It operates through the following segments: Retail, Specialty Distribution, and Other. The Retail segment offers insurance products and services to commercial, public and quasi-public entities, and to professional and individual customers. The Specialty Distribution segment consists of programs, wholesale brokerage, and specialty businesses. The company was founded by J. Adrian Brown and Charles Covington Owen in 1939 and is headquartered in Daytona Beach, FL.

Brown & Brown, Inc.

Brown & Brown Inc

Brown & Brown is trending as investors weigh strong earnings and consistent revenue growth against recent share price volatility and broader insurance sector headwinds. The community is actively debating whether the stock's current valuation offers a compelling entry point or signals a fundamental shift in its long-term growth trajectory.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention following the announcement of the preliminary design for its Phase 3 CAD-1005 trial targeting heparin-induced thrombocytopenia. While some investors are optimistic about the potential clinical milestones, others in the community are actively raising concerns regarding recent promotional spam and the company's long-term cash position.

Axelar delivers secure interchain communication. That means dApp users can interact with any asset, any application, on any chain, with one click. You can think of it as Stripe for Web3. Developers interact with a simple API atop a permissionless network that routes messages and ensures network security via proof-of-stake consensus.  Axelar is a blockchain that connects blockchains. To do this securely, Axelar network uses proof-of-stake consensus. Network validators produce new blocks, participate in multiparty signing and vote on external chain states. Tokenholders stake the AXL token, delegating tokens to a validator’s staking pool and receiving rewards, minus the validator’s commission.  The AXL token is used for governance and to pay network transaction fees to validators and tokenholders. However, users of the Axelar network do not need to hold the token. Conversions into AXL tokens and destination-chain tokens are handled on the back end, so that users need only pay gas once, in the source-chain token.  Axelar network rewards are “inflationary” — they increase the total supply of AXL — but there is potential for supply to become deflationary based on the transaction fee mechanic described above.

Axelar

Axelar is capturing community attention following the launch of a new XRPL EVM sidechain integration, which investors view as a pivotal step in expanding the network's utility. While some holders express frustration over recent price volatility and token dilution concerns, many remain focused on the project's long-term interoperability potential and its role in connecting major blockchain ecosystems.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is attracting significant community attention due to its role as infrastructure for autonomous AI agents on the Base ecosystem, with investors highlighting its ongoing development and utility as key long-term catalysts. While the token is seeing volatility, discussions are dominated by optimism regarding its ecosystem growth, revenue generation, and strategic positioning compared to meme-heavy projects.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy is actively discussing the $MULN ticker, with the community largely split between long-term holders awaiting a potential turnaround and skeptics warning against the project based on the company's past history of dilution and reverse splits. Conversation is fueled by high-volatility trading and coordinated efforts to trend the ticker, as participants debate the viability of this asset as a speculative crypto play.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

BridgeBio Pharma is currently trending as investors monitor recent institutional activity, including significant stake increases by major asset managers, alongside a favorable patent settlement for a key industry competitor that improves the long-term outlook for the company's heart disease drug. Community discussions are heavily focused on the stock's potential for an institutional-led rally, with market participants eagerly awaiting upcoming quarterly results and data readouts for its core pipeline assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AMRSQ

Reposting a valuation model that I shared in Henrik&#39;s Seeking Alpha article. Let me know if you agree with my model. 

Part 1 

Many struggle to put an objective, data-driven valuation on Amyris. Here’s my effort to do just that.

To begin, I’ll be building my model from Amyris’ consumer and ingredients business AND using TTM (trailing twelve months) revenue as my baseline. For the purposes of this model, I’ll be using Estee Lauder’s EV/Sales aka enterprise value to sales ratio of 6.8X.

Estee Lauder (EL) enterprise value to sales ratio - https://koyfin.com/s/oWYHF02FqU
Amyris’ C&amp;I valuation based on Estee Lauder revenue multiple - https://i.postimg.cc/RFQZ6s3X/Screen-Shot-2020-11-09-at-12-43-33-PM.png

Why Estee Lauder? At the moment, Amyris’ C&amp;I business has a heavy focus on skincare and fragrances so this seems like a reasonable business to compare to. I personally think it’s a conservative multiple since Amyris is a synthetic biology company that should be valued more like the following peer companies:

Tom Cross

K Fujii

Joseph Rivera

Outofcontrol

AddieMac

gina

Ben M

fernando

Martin999999

Salesmaster99

Koyfin

Postimg

Screen Shot 2020 11 09 at 12 43 33 PM - Postimages

StockTwits Web

Amyris Inc

$AMRS

Reposting a valuation model that I shared in Henrik's Seeking Alpha article. Let me know if you agree with my model. 

Part 1 

Many struggle to put an objective, data-driven valuation on Amyris. Here’s my effort to do just that.

To begin, I’ll be building my model from Amyris’ consumer and ingredients business AND using TTM (trailing twelve months) revenue as my baseline. For the purposes of this model, I’ll be using Estee Lauder’s EV/Sales aka enterprise value to sales ratio of 6.8X.

Estee Lauder (EL) enterprise value to sales ratio - 


Amyris’ C&I valuation based on Estee Lauder revenue multiple - 



Why Estee Lauder? At the moment, Amyris’ C&I business has a heavy focus on skincare and fragrances so this seems like a reasonable business to compare to. I personally think it’s a conservative multiple since Amyris is a synthetic biology company that should be valued more like the following peer companies:

GreenAndGreen

 Part 2

BLI - https://koyfin.com/s/2TtlQFsAg1
CDXS - https://koyfin.com/s/8iCfwxzFgL
TWST - https://koyfin.com/s/BwMhd1ThRX

With the model established, I’ve created a visual representation of Amyris’ actual EV with the valuation of the C&amp;I business overlaid. The vertical lines are end-of-quarter and the green arrows are the value of the C&amp;I business at the time using Estee Lauder’s 6.8x EV/Sales multiple.

See here - https://koyfin.com/s/JqTTdpjGo9

You’ll notice that I’ve modeled Q4 of 2020 using a pedestrian $35M in C&amp;I revenue. That means that the C&amp;I business (at minimum) justifies the current EV of the company. The C&amp;I “safety net” as it may be called continues to grow with time which will limit Amyris’ downside.

My conclusion (which hasn’t changed) is that this model shows that Amyris has limited downside and substantial upside.

T_Woo

BearGuru

N808



With the model established, I’ve created a visual representation of Amyris’ actual EV with the valuation of the C&I business overlaid. The vertical lines are end-of-quarter and the green arrows are the value of the C&I business at the time using Estee Lauder’s 6.8x EV/Sales multiple.

See here - 



You’ll notice that I’ve modeled Q4 of 2020 using a pedestrian $35M in C&I revenue. That means that the C&I business (at minimum) justifies the current EV of the company. The C&I “safety net” as it may be called continues to grow with time which will limit Amyris’ downside.

My conclusion (which hasn’t changed) is that this model shows that Amyris has limited downside and substantial upside.

@GreenAndGreen 
thank you for your contributions to this stocktwits board !!!

 
thank you for your contributions to this stocktwits board !!!

@GreenAndGreen - Bravo with Estee Lauder - check this article on  its brand highlights after being in China for the last couple of years:  https://www.alizila.com/tmall-success-a-talking-point-on-company-earnings-calls/    - Also upcoming live discussion on Pipette&#39;s launch in two days on &quot;Single Days&quot; - Next ER call could be eye-opening if they get great exposure! https://www.linkedin.com/feed/hashtag/?keywords=double11

Abercrombie & Fitch "[We are] building a better strategy for Tmall versus what we had in the past. So we think it's a huge long-term opportunity for the company. We've had nice growth to this point but looking forward to accelerating that in the future."

Alizila.com

International Brands Highlight Tmall Successes During Earnings Calls

500 million+ members | Manage your professional identity. Build and engage with your professional network. Access knowledge, insights and opportunities.

Linkedin

Sign Up | LinkedIn

 - Bravo with Estee Lauder - check this article on  its brand highlights after being in China for the last couple of years:  

    - Also upcoming live discussion on Pipette's launch in two days on "Single Days" - Next ER call could be eye-opening if they get great exposure! 